Clinical and laboratory predictors of effectiveness of background therapy in rheumatoid arthritis
- 作者: Dotsenko S.S1, Shilova L.N1
-
隶属关系:
- FSBEI HE "Volgograd State Medical University" of RMH
- 期: 编号 19 (2017)
- 页面: 53-56
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/290033
- ID: 290033
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The evaluation of clinical and laboratory predictors of the effectiveness of combination therapy with methotrexate and infliximab in rheumatoid arthritis (RA) was performed. A 30-week study included 18 patients with RA. It has been established that background anti-inflammatory therapy in combination with genetically engineered biologic drugs leads to a significant improvement in clinical and laboratory indicators (a marked decrease in the of acute phase inflammatory marker levels, normalization of the hemogram) and the quality of life of patients with high RA activity.
全文:
作者简介
S. Dotsenko
FSBEI HE "Volgograd State Medical University" of RMH
Email: svetlanahime@yandex.ru
Postgraduate Student at the Department of Hospital Therapy, MFT with the course of Clinical Rheumatology DIF
L. Shilova
FSBEI HE "Volgograd State Medical University" of RMH
参考
- Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primar for clinicians. 3rd edition. Amgen Inc. 2002. P. 351.
- Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. New Engl. J. Med. 2004;350:2167-79.
- El-Gabalawy H.S., Lipsky P.E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004;4(Suppl. 2):297-301.
- Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ. 2001;9:7-9.
- Lorenz H.M., Kalden J.R. Perspectives for TNFa targeting therapies. Arthritis Res. 2002; 4:S17-24.
- Kalden J.R. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Res. 2002;4:34-40.
补充文件
